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http://dx.doi.org/1to 48 hours can improve the detection of arrhythmias, lead-based (Holter) monitors might be
limited by patient compliance and other factors. We, therefore, evaluated compliance,
analyzable signal time, interval to arrhythmia detection, and diagnostic yield of the Zio
Patch, a novel leadless, electrocardiographic monitoring device in 26,751 consecutive
patients. The mean wear time was 7.6 – 3.6 days, and the median analyzable time was 99% of
the total wear time. Among the patients with detected arrhythmias (60.3% of all patients),
29.9% had their ﬁrst arrhythmia and 51.1% had their ﬁrst symptom-triggered arrhythmia
occur after the initial 48-hour period. Compared with the ﬁrst 48 hours of monitoring, the
overall diagnostic yield was greater when data from the entire Zio Patch wear duration were
included for any arrhythmia (62.2% vs 43.9%, p <0.0001) and for any symptomatic
arrhythmia (9.7% vs 4.4%, p <0.0001). For paroxysmal atrial ﬁbrillation (AF), the mean
interval to the ﬁrst detection of AF was inversely proportional to the total AF burden, with an
increasing proportion occurring after 48 hours (11.2%, 10.5%, 20.8%, and 38.0% for an AF
burden of 51% to 75%, 26% to 50%, 1% to 25%, and <1%, respectively). In conclusion,
extended monitoring with the Zio Patch for £14 days is feasible, with high patient compli-
ance, a high analyzable signal time, and an incremental diagnostic yield beyond 48 hours for
all arrhythmia types. These ﬁndings could have signiﬁcant implications for device
selection, monitoring duration, and care pathways for arrhythmia evaluation and AF
surveillance.Published by Elsevier Inc. (Am J Cardiol 2013;112:Open access under CC BY-NC-ND license. -
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Ambulatory electrocardiography is a widely used diag-
nostic tool to detect arrhythmias for a variety of symptoms
and conditions.1e3 Because of memory and technical limi-
tations, ambulatory electrocardiographic (ECG) monitors
have historically provided either short-term (24 to 48 hour)
continuous monitoring (Holter) or longer term intermittent
(triggered) monitoring (event or loop recorder).3,4 Contin-
uous ECG monitoring longer than the traditional 24- to
48-hour duration might improve the diagnostic yield of
infrequent arrhythmias. However, such technologies have
generally been limited by patient compliance, the analyzable
3e9electrode skin irritation. We, therefore,
e patient compliance, device analyzable time,
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Open access under CC BY-NC-ND licand diagnostic yield of a novel, leadless, wearable monitor
for extended ambulatory ECG monitoring.
Methods
We performed a cross-sectional study of patients
receiving a single-use, long-term, continuous, cardiac
monitoring patch for clinical indications. The Zio Patch
monitor (iRhythm Technologies, San Francisco, California)
is a compact (123  53  10.7 mm), lightweight (34 g), and
water-resistant, cutaneous single-lead ECG monitor that
provides 14 days of continuous ECG data obtained from
a single vector. The single-use device is placed over the
patient’s left pectoral region with skin adhesive and is
typically applied by trained technicians at the ordering
ambulatory clinic. A button can be pressed by the patient to
annotate symptoms (Figure 1). After completion of the
monitoring period, the patient mails the device and diary to
the data processing center, where the data are analyzed, and
a report is generated and sent to the ordering physician.
We obtained de-identiﬁed data from the device manu-
facturer and servicer (iRhythm Technologies) for all patients
who had completed Zio Patch monitoring for clinical indi-
cations from January 1, 2011 to December 31, 2011. These
data were transferred to us after removal of all patient-,
physician-, and site-level identiﬁers. We included all Zio
Patch data from consecutive patients receiving ﬁrst-time
patches at the enrolling site. We excluded data for repeated
or subsequent Zio Patch monitoring to minimize con-
founding by indication. A local institutional review board
and the Veterans Affairs Palo Alto Health Care System
www.ajconline.orgense.
Figure 1. Zio Patch button and placement. (A) Patients can press a button on the Zio Patch to mark a symptomatic episode. (B) The device is placed over the
patient’s left pectoral region. (Images courtesy of iRhythm Technologies, Inc., San Francisco, California.)
Table 1
Provider-reported clinical indications
Variable Patients (n)
Palpitations 10,786 (40.3)
AF 6,493 (24.3)
Syncope or presyncope 4,029 (15.1)
Bradycardia 964 (3.6)
SVT 570 (2.1)
Unspeciﬁed tachycardia 547 (2.1)
VT 187 (0.7)
Pause 48 (0.2)
AV block* 44 (0.2)
Polymorphic VT, torsade de pointes, VF 6 (0.0)
Other indications† 3,557 (13.4)
Data in parentheses are percentages.
Clinical indications for ambulatory electrocardiography monitoring were
ascertained from a free-text variable provided by the ordering provider;
patients could have >1 clinical indication for cardiac monitoring.
AV ¼ atrioventricular; VF ¼ ventricular ﬁbrillation.
* Second-degree Mobitz II or third-degree AV block.
† Providers reported unspeciﬁed arrhythmias, nonarrhythmic cardiovascular
indications, or no indication, exclusive of indications listed.
Table 2
Detected arrhythmias
Variable Patients (n) All Patients
With
Arrhythmia (%)
Women
(%)
Detected arrhythmias
(excluding chronic AF)
16,142 (60.3) 100.0 52.0
Single arrhythmias
(excluding chronic AF)
12,298 (46.0) 76.2 56.5
Multiple arrhythmias
(excluding chronic AF)
3,083 (11.5) 19.1 39.7
Chronic AF 2,003 (7.5) — 39.4
No other arrhythmias 1,242 (4.6) — 45.2
1 Other arrhythmias 761 (2.8) 4.7 30.0
No arrhythmia 10,609 (39.7) — 58.3
Data in parentheses are percentages.
Arrhythmias, excluding chronic AF, were detected in 60.3% of patients;
men were more likely than women to have chronic AF, 1 arrhythmias in
addition to chronic AF, or multiple arrhythmias (excluding chronic AF).
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study.
The clinical indication for monitoring was ascertained
from a free-text variable that was entered by the ordering
provider. Trained research staff aggregated the indications
into 11 categories: palpitations, AF, syncope or presyncope,
bradycardia, supraventricular tachycardia (SVT), unspeci-
ﬁed tachycardia, ventricular tachycardia (VT), pause,
second degree Mobitz II or third degree (complete) atrio-
ventricular block, polymorphic VT (including torsade de
pointes and ventricular ﬁbrillation), and other indications. If
a patient had >1 clinical indication, all indications were
retained for analysis.
Arrhythmia adjudication was performed and coded using
a 2-step process. First, the servicer applied a digital signal
processing algorithm to continuously recorded ECG data to
identify potential arrhythmia episodes. The algorithm, cleared
using the 510(k) method by the Food and Drug Administra-
tion for clinical use, detects potential arrhythmias by detectionof the heart rate, irregularity, and morphology. The algorithm
then uses the heart rate increase from the preceding portion of
heart rate regularity (sinus rhythm) to conﬁrm a candidate
episode. Next, trained and certiﬁed cardiovascular technicians
employed by the servicer re-examined the detected
arrhythmia episodes to conﬁrm the diagnoses and to classify
the arrhythmia where appropriate. Because the algorithm
assigns an arrhythmia classiﬁcation to every portion of the
continuous recording, a second detected rhythm (including
artifact) occurring in the middle of an arrhythmia event can
cause the event to be classiﬁed as multiple discrete episodes.
These episodes are reclassiﬁed on review by technicians to
a single arrhythmia event, when appropriate. Arrhythmia
adjudication was performed for clinical ﬁndings by techni-
cians with no knowledge of the present study.
The episodes were classiﬁed into 3 categories according to
the type of arrhythmia: ﬁrst occurrence, ﬁrst symptomatic
occurrence (if occurring 45 seconds before or after patient
triggering), and longest duration. The arrhythmias were clas-
siﬁed into the following independent, but not mutually exclu-
sive, categories: atrial ﬁbrillation (AF), pause >3 seconds,
second-degree Mobitz II or complete atrioventricular
Table 3
Prevalence of detected arrhythmias
Variable All
Patients
(%)
All Patients
With
Arrhythmia (%)
Women
(%)
Time to First Arrhythmia Time to First Symptomatic Arrhythmia
Mean  SD
(days)
Median (IQR) Occurring After
48 hrs (%)
Mean  SD
(days)
Median (IQR) Occurring After
48 hrs (%)
Any arrhythmia 60.3 100.0 52.0 1.7  2.2 0.8 (0.2e2.4) 29.9 3.0  2.9 2.1 (0.8e4.4) 51.1
Atrial ﬁbrillation
burden (%)
17.3 28.7 41.0 1.4  2.1 0.4 (0.1e1.8) 23.4 2.7  2.8 1.8 (0.6e4.0) 47.2
<1 2.9 4.8 46.2 2.2  2.7 1.2 (0.3e3.3) 38.0 3.8  3.6 2.7 (0.9e5.7) 57.4
1e25 4.8 7.9 41.1 1.2  1.8 0.4 (0.1e1.5) 20.8 3.2  2.9 2.3 (0.9e4.7) 56.5
26e50 1.3 2.1 40.4 0.7  1.3 0.1 (0e0.6) 10.5 2.6  2.8 1.5 (0.4e3.9) 40.4
51e75 0.6 1.0 35.4 0.6  1.2 <0.1 (0e0.6) 11.2 2.2  2.2 1.6 (0.6e3.3) 39.3
76e99 0.3 0.4 43.0 0.2  0.4 <0.1 (0e0.3) 1.4 1.8  2.9 0.7 (0.2e1.7) 23.1
100 (chronic AF) 7.5 — 39.4 — — — — — —
Pause >3 s 3.7 6.1 38.9 2.8  2.9 1.7 (0.6e4.0) 46.6 3.0  3.1 1.8 (0.8e5.1) 42.9
Mobitz II or complete
AV block
1.4 2.3 37.3 2.2  2.9 1.0 (0.3e2.7) 34.1 2.3  2.8 1.0 (0.6e3.1) 36.6
SVT (beats)
4 45.9 76.1 56.1 1.9  2.3 1.0 (0.3e2.6) 32.3 3.4  3.0 2.5 (1.1e5.1) 59.1
8 30.8 51.1 57.1 1.4  1.9 0.6 (0.2e1.8) 23.3 3.3  2.9 2.3 (1.0e4.9) 58.0
VT (beats)
4 12.3 20.4 36.1 3.4  3.2 2.6 (0.9e5.2) 58.3 3.7  3.1 3.0 (1.1e5.6) 63.3
8 4.7 7.8 34.7 3.0  3.0 2.1 (0.5e4.6) 51.2 3.6  3.2 2.7 (1.0e5.6) 61.0
Excluding chronic AF, the mean time to ﬁrst arrhythmia and ﬁrst symptom-triggered arrhythmia was 1.7  2.2 days and 3.0  2.9 days, respectively; the
median time to ﬁrst arrhythmia and ﬁrst symptom-triggered arrhythmia was 0.8 day (IQR 0.2e2.4) and 2.1 days (IQR 0.8e4.4), respectively; 29.9% of ﬁrst
arrhythmias and 51.1% of ﬁrst symptom-triggered arrhythmias occurred >48 hours after the start of monitoring; patients with a low AF burden had a longer
time to detection; 27.4% of patients with an AF burden 25% had their ﬁrst AF episode beyond 48 hours, and 56.8% of patients with an AF burden of 25%
had their ﬁrst symptomatic AF episode beyond 48 hours.
AV ¼ atrioventricular; IQR ¼ interquartile range.
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burden was further calculated as the percentage of
analyzable time. We segmented the AF burden into the
following categories of paroxysmal AF (<1%, 1% to 25%,
26% to 50%, 51% to 75%, and 76% to 99%) and chronic
AF (100%). For analytical purposes, we did not count
chronic AF as an arrhythmia event or toward the diag-
nostic yield. This method has been shown to have excel-
lent agreement with simultaneously acquired Holter
recordings for the detection of AF (k ¼ 1.0) and quanti-
ﬁcation of AF burden (r ¼ 0.96).10
The total wear time was calculated from the point of
activation to the point of the last recorded analyzable signal.
Wear time end points of 2, 6, and 13 days were used to
mark the comparison points of the typical 48 hours (Holter),
1 week, and 2 weeks of ECG monitoring. The device
analyzable time fraction was deﬁned as the proportion of the
total wear time that the ECG signal is interpretable (sufﬁ-
ciently free of noise) by the arrhythmia detection algorithm.
Descriptive statistics were performed using STATA,
version 11 (StataCorp, College Station, Texas) for analysis.
Continuous variables and proportions were compared using
the t test and chi-square test, respectively, and p <0.05 was
considered signiﬁcant. All analyses were performed by 2 of
us (D.D.H., M.P.T.) and were independently veriﬁed and
reproduced by a second statistician (X.X.).
Results
Of the 28,038 consecutive Zio Patch studies from January
2011 to December 2011, we included 26,751 ﬁrst-timestudies (95.4%) of unique patients and excluded 1,287 repeat
studies from the present analysis.
The mean age was 60.2  18.7 years, and 54.5% of the
patients were women. The mean wear time was 7.6  3.6
days. The median wear time was 7.0 days (25th to 75th
percentile interquartile range 5.9 to 9.3); 95.9% wore the
device >48 hours, 74.3% wore the device 6 days, and
16.1% wore the device 13 days. The median analyzable
time, expressed as a percentage of the total wear time, was
99% (interquartile range 94% to 99%); 87.1% of the patients
had an analyzable time the equivalent of 22 hr/day. No
signiﬁcant difference was found in age or wear time
between the genders.
The provider-reported clinical indications are listed in
Table 1; the most prevalent indications were palpitations,
atrial ﬁbrillation, and syncope or presyncope.
The overall prevalence of single andmultiple arrhythmias is
listed in Table 2. Arrhythmias, not counting chronic AF, were
detected in 16,142 patients (60.3%). Of all the patients, 12,298
(46.0%) had a single arrhythmia and 3,083 (11.5%) had
multiple arrhythmias (not including chronic AF). Chronic AF
was present in 2,003 patients (7.5%), and 761 of these patients
(2.8%) had other arrhythmias, in addition to chronic AF.
The distribution and time to the detection of each cate-
gory of asymptomatic arrhythmias are listed in Table 3.
Overall, the mean and median time to the ﬁrst arrhythmia
was 1.7  2.2 days and 0.8 day (interquartile range 0.2 to
2.4), and the mean and median time to the ﬁrst symptom-
triggered arrhythmia was 3.0  2.9 days and 2.1 days
(interquartile range 0.8 to 4.4), respectively. Among the
patients with arrhythmias, the most common was SVT.
Figure 2. Time to ﬁrst AF and ﬁrst symptomatic AF stratiﬁed by AF burden.
The bottom, middle, and top lines of each box correspond to the 25th, 50th
(median), and 75th percentile, respectively. The whisker caps mark 1.5 times
the interquartile range below the 25th percentile and 1.5 times the inter-
quartile range above the 75th percentile. For all nonchronic AF, the time to
ﬁrst detection was 2.7  2.8 days. The smaller the AF burden, the longer the
mean time to ﬁrst detection. The mean time to the ﬁrst diagnosis of AF ranged
from 0.2  0.4 day for an AF burden of 76% to 99% (1.4% after 48 hours) to
2.2  2.7 days for an AF burden <1% (38.0% after 48 hours). Likewise,
a longer time to the ﬁrst symptomatic episode of AF was associated with
a decreased AF burden. The mean time to the ﬁrst diagnosis of symptomatic
AF ranged from 1.8 2.9 days for an AF burden of 76% to 99% (23.1% after
48 hours) to 3.8  3.6 days for an AF burden <1% (57.4% after 48 hours).
Figure 3. Cumulative yield of arrhythmia detection over time. Among
patients with arrhythmias, regardless of symptoms, 90% had arrhythmia
identiﬁed by the ﬁfth day of monitoring; only 71% did so in the ﬁrst 2 days
of monitoring. The trends were similar for symptom-triggered arrhythmias,
with a 90% yield by 8 days of monitoring.
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ﬁrst symptom-triggered arrhythmia is listed in Table 3.
Overall, the variation in the time to the ﬁrst event for all
arrhythmias types was wide. Among the patients with
arrhythmias, 29.9% had their ﬁrst arrhythmia occur
>48 hours from the start of monitoring. Among the patients
with symptom-triggered arrhythmias (Table 3), 51.1%
occurred >48 hours from the start of monitoring (Table 3).
The diagnostic yield of pauses, Mobitz II or complete
atrioventricular block, SVT, and VT all improved with
extended monitoring (Table 3).Excluding chronic AF, the time to the detection of the
ﬁrst AF was 2.7  2.8 days. The time to AF detection was
inversely proportional to the total AF burden. As the burden
of AF decreased, the mean time to the ﬁrst detection
increased, with an increasing proportion occurring after
48 hours, ranging from 0.2  0.4 days for an AF burden of
76% to 99% (1.4% after 48 hours) to 2.2  2.7 days for an
AF burden <1% (38.0% after 48 hours; Figure 2). The
ﬁndings were similar for the time to the ﬁrst symptom-
triggered AF episode.
Figure 3 illustrates the cumulative yield of arrhythmias
over time. Among patients with arrhythmias, regardless of
symptoms, only 71.1% had arrhythmias identiﬁed in the ﬁrst
2 days of monitoring (Figure 3). By the ﬁfth day of moni-
toring, 90% of all patients with arrhythmias through the end
of monitoring were identiﬁed. Among the patients with
symptomatic arrhythmias, 92% of patients with arrhythmias
through the end of follow-up were detected by the eighth
day compared with only 46.5% in the ﬁrst 2 days (Figure 3).
Because patients might discontinue monitoring after the ﬁrst
symptomatic arrhythmia, we also evaluated the subgroup of
patients who wore the patch for 13 days. In this subgroup,
12 days of monitoring were required to capture 90% of all
patients with arrhythmias.Discussion
In the present study of 26,751 patients with ﬁrst-time,
patch-based (leadless) ambulatory ECG monitoring for
clinical indications, we found high patient compliance (wear
time), a high analyzable time, and a large portion of
arrhythmias identiﬁed beyond the ﬁrst 48 hours of moni-
toring. These ﬁndings were consistent across all arrhythmia
types and among the subset of symptom-triggered arrhyth-
mias. These ﬁndings indicate that extended monitoring with
the Zio Patch is feasible and identiﬁes arrhythmias that
could be missed with traditional 48-hour monitoring.
The relatively high wear time and analyzable time of the
Zio Patch might have resulted from the practical beneﬁts of
patch-based monitoring compared with the traditional
design of the “Holter” style monitors, with detachable leads,
removable skin electrodes, and a recording unit. Previous
studies have reported substantially reduced compliance with
lead-based extended monitoring (Holter, event monitors,
and mobile cardiac outpatient telemetry devices) because of
the high rates of skin irritation, difﬁculty of use, and
disruption to the patient’s work, travel, or lifestyle.5,11e13
Wired monitors with temporary electrodes are also suscep-
tible to motion artifact, which can limit the interpretability
during exercise and must be removed before showering or
contact with water. In the present study, although 74% wore
the device for 6 days, 16% wore the device for the
maximum duration (>13 days). The reasons for this were
multifactorial, including a shift in the manufacturer’s
recommendations from 7 days of monitoring to 14 days
during the study period and variations in provider prefer-
ences or instructions. The mean wear time increased from 7
to 9 days during the study period. The Zio Patch’s small
size, absence of wired leads, and water resistance could have
contributed to the patient compliance and signal quality.
524 The American Journal of Cardiology (www.ajconline.org)For all arrhythmia types, the diagnostic yield increased
with monitoring beyond 48 hours. Among patients with
paroxysmal AF, the time to the detection of the ﬁrst AF
episode increased as the total AF burden decreased. Our
ﬁndings are consistent with those from a small, single-
center study of patients with known AF who concurrently
wore Zio Patches and 24-hour Holter monitors.10 They
found that compared with 24-hour Holter monitoring, AF
events were identiﬁed in 18 of 70 subjects after Zio Patch
monitoring; 21 patients had a change in clinical manage-
ment because of reclassiﬁcation by the Zio results.
Therefore, these ﬁndings could have signiﬁcant implica-
tions for minimizing repeat testing, assessing treatment
response, and expediting appropriate therapy, such as
anticoagulation.
Previous studies have also shown that continuous moni-
toring with implantable loop recorders increase the diagnostic
yield for AF recurrence after catheter ablation, cardioversion,
or initiation of antiarrhythmic drug therapy.14,15 However,
our data have indicated that 14 days of monitoring can
substantially improve AF detection in paroxysmal AF, even
when the observed AF burden was <15%. Therefore, cuta-
neous patch-based monitoring should be investigated further
as a potential alternative before implantation of an implant-
able loop recorder or mobile cardiac outpatient telemetry,
particularly if real-time transmission, which is not available
with the Zio Patch, is not required.
Our study had several limitations. First, our retrospective
study of patients who received a Zio Patch for clinical
indications might not reﬂect the epidemiology of all patients
presenting for ECG monitoring, because clinical suspicion
of arrhythmia frequency could have informed the device
selection at certain sites. Second, arrhythmia episodes of
relatively short duration were included in our SVT and VT
categorizations. It is possible that the identiﬁcation of some
of these episodes, even if detected with extended moni-
toring, might not be clinically important. However, the
ﬁndings for symptom-triggered arrhythmias of short dura-
tion were signiﬁcant and consistent with the overall results.
Finally, although previous studies have shown excellent
agreement between simultaneous Zio and Holter recordings
for AF,10 differences in signal processing and detection
algorithms could have led to variation in the agreement of
arrhythmia detection and classiﬁcation across the Zio Patch
and other monitoring devices, although the variation would
be expected to be low.Disclosures
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